Crucell N.V.

OVERVIEW |  NEWS |  MULTIMEDIA  | RESEARCH

---

Crucell N.V. Company Summary

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharma company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.

COMPANY DATA

	Principal Sector	Health & Pharm
	Principal Industry	None
	Homepage	www.crucell.com

---

Key Developments: Crucell N.V.

	Crucell N.V. (AMS:CRXL) Crucell Announces Third Quarter 2008 Results NOV 11, 2008 16:49 - Article Views: 298 Crucell N.V. (AMS:CRXL) Crucell achieves profitability in Q3 2008. Crucell announces third quarter 2008 results with net income of €12.3 million. Total revenue and other operating income increased by 31% to €82.1 million compared to the same quarter last year. Gross margin in the third quarter mproved to 50% (from 36% last year). 2008 full year guidance for total revenue and other operating income growth increased to 25-30% in constant currencies (from 20%).
	Crucell N.V. (AMS:CRXL) Crucell To Release Q3 2008 Earnings On Tuesday, November 11, 2008 NOV 4, 2008 23:03 - Article Views: 230 Crucell N.V. (AMS:CRXL) Leiden, The Netherlands (November 4, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it will release its financial results for the third quarter of 2008 on Tuesday, November 11, 2008 at 07:45 Central European Time (CET).
	Crucell N.V. (AMS:CRXL) Crucell Doubles Production Of Quinvaxem® In 2008 And Prepares Move To New Korean Production Site To Facilitate Growth OCT 21, 2008 21:03 - Article Views: 248 Crucell N.V. (AMS:CRXL) Leiden, The Netherlands, 21 October 2008 - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that an agreement was reached to relocate Crucell's Korean production facility, where its pentavalent children's vaccine Quinvaxem® and a hepatitis B vaccine Hepavax-Gene® are produced, from the Shingal site in Yongin City, Korea to the Incheon Free Economic Zone.
	Crucell N.V. (AMS:CRXL) Aeras And Crucell Announce TB Vaccine Clinical Trial In Kenya; Promising Vaccine Candidate Advances To Phase II Safety Study In South Africa OCT 17, 2008 15:47 - Article Views: 232 Crucell N.V. (AMS:CRXL) Leiden, The Netherlands/Paris, France, 17 October 2008 - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) and the Aeras Global TB Vaccine Foundation today announce the start of a Phase I clinical trial in Kenya of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35. The announcement is made in the lead up to the 39th Union World Conference on Tuberculosis and Lung Disease in Paris, France (16-20 October, 2008).
	Crucell N.V. (AMS:CRXL) Crucell Receives NIAID/NIH Contract For Development Of Ebola And Marburg Vaccines OCT 3, 2008 18:03 - Article Views: 299 Crucell N.V. (AMS:CRXL) Leiden, The Netherlands (October 3, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it received a National Institutes of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) contract aimed at advancing the development of a multivalent filovirus vaccine that includes both Ebola and Marburg viruses. The contract provides funding of up to $30 million, with additional options that may be triggered at the discretion of the NIH worth a further $40 million.
	Crucell N.V. (AMS:CRXL) Crucell Announces Positive Results Of Phase II Clinical Study Rabies Monoclonal Antibody Combination In US OCT 2, 2008 05:33 - Article Views: 270 Crucell N.V. (AMS:CRXL) Additional Milestone Achieved in Collaboration Agreement with sanofi pasteur
	Crucell N.V. (AMS:CRXL) DSM And Crucell Announce Another Key Achievement For PER.C6® Technology; Scale Up Of High-titer Fed-Batch Process To 250 Liters SEP 29, 2008 22:03 - Article Views: 213 Crucell N.V. (AMS:CRXL) Groningen/Leiden, The Netherlands; Parsippany, USA, 29 September 2008 - DSM Biologics and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that the high-titer fed-batch process developed at the PERCIVIA PER.C6® Development Center, their joint venture in Cambridge, USA was recently scaled up to 250 liters by DSM Biologics scientists at their GMP facility in Groningen, The Netherlands. They successfully achieved 8 grams per liter for an IgG expressed by PER.C6® cells using chemically defined cell culture medium in a SUB (single-use bioreactor).
	Crucell N.V. (AMS:CRXL) Crucell's Swiss Affiliate Berna Biotech To Cease All Animal Testing SEP 26, 2008 15:47 - Article Views: 268 Crucell N.V. (AMS:CRXL) Leiden, The Netherlands (September 26, 2008) - For several years the vaccine producer Berna Biotech a Swiss affiliate of Crucell N.V. has been working rigorously on the 3R program, which has a goal to Reduce, Refine and Replace all animal testing. The development of in-vitro alternatives as well as the strategic imperative of Berna Biotech to eliminate animal testing has resulted in the company announcing, that it will cease all animal testing and therefore close the animal house in Bern in 2008. Crucell's Swiss affiliate Berna Biotech whose goal is to fight infectious diseases and save lives by bringing innovation to global health has reached another important milestone in the production of modern vaccines.
	Crucell N.V. (AMS:CRXL) Lonza And Crucell Enter Into Long Term Agreement SEP 25, 2008 15:33 - Article Views: 203 Crucell N.V. (AMS:CRXL) Basel, Switzerland / Leiden, The Netherlands (September 25, 2008) - Lonza (Swiss Exchange: LONN) and Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) entered into a co-exclusive manufacturing, sales and distribution agreement related to the PERMEXCIS(TM) cell culture medium developed by Crucell for PER.C6® cells. Under this agreement, Lonza will manufacture the medium, and in addition will market and sell it on a global basis. Financial details of the agreement were not disclosed.
	Crucell N.V. (AMS:CRXL) New Contracts Awarded For Quinvaxem® And Hepavax-Gene® SEP 23, 2008 15:47 - Article Views: 342 Crucell N.V. (AMS:CRXL) Leiden, The Netherlands (September 23, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that supranational organizations awarded Crucell new contracts of $140 million for supplies of Quinvaxem® and Hepavax-Gene® for the period 2008 - 2009, bringing the total for the period 2007 - 2009 to $0.5 billion.

339 COMPANY PROFILE VIEWS

This Page Viewed: (Last 7 Days: 4) (Last 30 Days: 17) (Since Published: 339)